Reuters logo
BRIEF-Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)
February 7, 2017 / 7:05 AM / 8 months ago

BRIEF-Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)

Feb 7 (Reuters) - Biofrontera AG :

* Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT)

* Results will be employed for the filing of the EU label extension, which Biofrontera plans to submit in the second quarter of 2017

Source text for Eikon:

Further company coverage:

Gdynia Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below